Kidney Transplant Recipients May Benefit From Early Remdesivir Treatment for COVID-19

Kidney transplant recipients who develop COVID-19 face unique risks, since their immune-suppressing medications can make infections more dangerous and complicate recovery. A new study published in JAMA Network Open suggests that starting the antiviral drug remdesivir early in the course of illness may help protect both the transplanted kidney and cardiovascular health in this vulnerable group.

The study, conducted across five hospitals within the Johns Hopkins Health System, followed 432 adult kidney transplant recipients who developed symptomatic COVID-19 between March 2020 and January 2024. Investigators used a method called target trial emulation, which applies rigorous statistical techniques to observational data to approximate the kind of evidence a formal clinical trial would provide. Patients who received other COVID-19 treatments, including certain antibody therapies and antiviral pills, were excluded so the team could isolate the effect of remdesivir specifically.

Participants were grouped based on their treatment path. Those who started remdesivir within seven days of diagnosis and completed at least three consecutive days of therapy were classified as receiving early treatment. Those who did not receive remdesivir at all made up the comparison group. Investigators then tracked outcomes for up to one year, focusing primarily on a combined measure of transplant failure and death, along with secondary outcomes including cardiovascular events and long COVID.

Among the participants, whose median age was 57 years, 177 patients received early remdesivir and 255 did not. Over the year of follow-up, patients who received early treatment had roughly half the risk of losing their kidney transplant or dying compared with those who did not receive remdesivir. Early treatment was also linked to a lower risk of cardiovascular events, including issues such as heart attack or stroke.

“Several biologically plausible mechanisms may explain the observed associations,” said first study author Karan Srisurapanont, M.D. “Early suppression of viral replication may reduce systemic inflammation, endothelial injury, or damage to blood vessels, and thrombotic complications, or those related to severe blood clotting, that may contribute to heart and kidney problems.”

The findings were less clear for two other outcomes. While early remdesivir use trended toward a lower risk of death from any cause, that association did not reach statistical significance on its own. The same was true for long COVID, meaning researchers could not confidently conclude that early treatment reduced the risk of lingering post-COVID symptoms based on these data.

The investigators noted that their findings support prompt initiation of remdesivir for kidney transplant recipients who develop COVID-19, particularly given the strong associations with graft survival and cardiovascular protection. Because kidney transplant patients were largely excluded or underrepresented in many of the original clinical trials that established COVID-19 treatment guidelines, this kind of real-world data helps fill an important gap in understanding how these therapies perform in immunosuppressed populations.

As with any observational study, the results show a strong association rather than definitive proof of cause and effect, and further research may help clarify how these findings apply across different patient populations and virus variants.

“These findings suggest that timely antiviral treatment may have benefits beyond the acute phase of COVID-19 in this population,” said senior investigator Nitipong Permpalung, M.D., M.P.H., associate director of the Johns Hopkins Transplant Research Center. “We hope these findings will help reduce hesitations that physicians may have with considering providing remdesivir, when clinically appropriate, to adult kidney transplant recipients.”